Advertisement

The European Journal of Health Economics

, Volume 19, Issue 9, pp 1365–1374 | Cite as

Economic evaluation of Zepatier for the management of HCV in the Italian scenario

  • F. R. Rolli
  • M. Ruggeri
  • F. Kheiraoui
  • C. Drago
  • M. Basile
  • C. Favaretti
  • A. Cicchetti
Original Paper

Abstract

Background

Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections.

Objective

Conducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis).

Methods

A Markov model was built on the natural history of the disease to assess the efficacy of the alternatives. The outcomes are expressed in terms of quality adjusted life-years (QALYs) and result in terms of incremental cost-effectiveness ratio).

Results

Elbasvir/grazoprevir implies an expenditure of €21,104,253.74 with a gain of 19,287.90 QALYs and sofosbuvir + pegylated interferon/ribavirin implies an expenditure of €31,904,410.11 with a gain of 18,855.96 QALYs. Elbasvir/grazoprevir is thus a dominant strategy.

Conclusion

Consideration should be given to the opportunity cost of not treating patients with a lower degree of fibrosis (F0–F2).

Keywords

Cost-effectiveness analysis ICER Sensitivity analysis Opportunity cost HCV 

JEL Classification

H51 Government expenditure and Health 

Notes

Author contributions

All authors made a substantial contribution to the conception, design, acquisition of data and related analysis and interpretation and participated in drafting the article and revising it critically and according to its important intellectual content.

Funding

The analysis was developed with the unconditioned support of MSD Italia S.r.l.. The views expressed here are those of the authors and not necessarily those of the funders.

Compliance with ethical standards

Conflict of interest

None of the authors (Drs. Rolli, Dr. Ruggeri, Drs. Kheiraoui, Dr. Drago, Dr. Basile, Drs. Favaretti, Dr. Cicchetti) has any potential conflict of interest related to this manuscript.

References

  1. 1.
    WHO: Global health sector strategy on viral hepatitis, 2016–2021. WHO, Geneva (2016)Google Scholar
  2. 2.
    Razavi, H., El Khoury, A.C., Elbasha, E., et al.: Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (Baltimore) 57, 2164–2170 (2013)CrossRefGoogle Scholar
  3. 3.
    Poynard, T., Ratziu, V., Benmanov, Y., Di Martino, V., Bedossa, P., Opolon, P.: Fibrosis in patients with hepatitis C: detection and significance. Semin. Liver Dis. 20(1), 0047–0056 (2000)CrossRefGoogle Scholar
  4. 4.
    Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H.: Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61(1 Suppl), S45–S57 (2014)CrossRefGoogle Scholar
  5. 5.
    Marcellusi, A., Viti, R., Capone, A., Mennini, F.S.: The economic burden of HCV-induced diseases in Italy: a probabilistic cost of illness model. Eur. Rev. Med. Pharmacol. Sci. 19, 1610–1620 (2015)PubMedGoogle Scholar
  6. 6.
    Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., Marcellin, P.: Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN- free treatment and future perspectives. Liver Int. 36(Suppl 1), 47–57 (2016)CrossRefGoogle Scholar
  7. 7.
    Shahid, I., Almalki, W.H., Hafeez, M.H., Hassan, S.: Hepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategies. Crit. Rev. Microbiol. 42(4), 535–547 (2016)PubMedGoogle Scholar
  8. 8.
    Chung, R.T., Baumert, T.F.: Curing chronic Hepatitis C—the arc of a medical triumph. N. Engl. J. Med. 370, 1576–1578 (2014)CrossRefGoogle Scholar
  9. 9.
    European Association for Study of Liver: EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 63(1), 199–236 (2015)CrossRefGoogle Scholar
  10. 10.
    Corman, S., Elbasha, E.H., Michalopulos, S.N., Nwanmkwo, C.: Cost-utility of elbasvir/grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value Health 20(8), 1110–1120 (2017)CrossRefGoogle Scholar
  11. 11.
    Kondili, L.A., Romano, F., Rolli, F.R., Ruggeri, M., Rosato, S., Brunetto, M.R., Zignego, A.L., Ciancio, A., Di Leo, A., Raimondo, G., Ferrari, C., Taliani, G., Borgia, G., Santantonio, T.A., Blanc, P., Gaeta, G.B., Gasbarrini, A., Chessa, L., Erne, E.M., Villa, E., Ieluzzi, D., Russo, F.P., Andreone, P., Vinci, M., Coppola, C., Chemello, L., Madonia, S., Verucchi, G., Persico, M., Zuin, M., Puoti, M., Alberti, A., Nardone, G., Massari, M., Montalto, G., Foti, G., Rumi, M.G., Quaranta, M.G., Cicchetti, A., Craxì, A., Vella, S., On behalf of PITER Collaborating Group: Modelling cost-effectiveness and health gains of a “universal” vs. “prioritized” HCV treatment policy in a real-life cohort. Hepatology 66(6), 1814–1825 (2017)CrossRefGoogle Scholar
  12. 12.
    Sperl, J., Horvath, G., Halota, W., Ruiz-Tapiador, J.A., Streinu- Cercel, A., Jancoriene, L., Werling, K., Kileng, H., Koklu, S., Gerstoft, J., Urbanek, P., Flisiak, R., Leiva, R., Kazenaite, E., Prinzing, R., Patel, S., Qiu, J., Asante-Appiah, E., Wahl, J., Nguyen, B.Y., Barr, E., Platt, H.L.: Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J. Hepatol. 65(6), 1112–1119 (2016)CrossRefGoogle Scholar
  13. 13.
    Cenderello, G., Artioli, S., Viscoli, C., Pasa, A., Giacomini, M., Gini, B., Dentone, C., Nicolini, L.A., Cassola, G., Di Biagio, A.: Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon. Outcomes Res. 31(8), 15–21 (2015)CrossRefGoogle Scholar
  14. 14.
    Sonnenberg, F.A., Beck, J.R.: Markov models in medical decision making: a practical guide. Med. Decis. Making 13, 322–338 (1993)CrossRefGoogle Scholar
  15. 15.
    Alagoz, O., Hsu, H., Schaefer, A.J., Roberts, M.S.: Markov decision processes: a tool for sequential decision making under uncertainty. Med. Decis. Making 30(4), 474–483 (2010)CrossRefGoogle Scholar
  16. 16.
    Wright, M., Grieve, R., Roberts, J.: UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1–113 (2006)CrossRefGoogle Scholar
  17. 17.
    Ruggeri, M., Coretti, S., Gasbarrini, A., Cicchetti, A.: Economic assessment of an anti-HCV screening program in Italy. Value Health 16(6), 965–972 (2013)CrossRefGoogle Scholar
  18. 18.
    Romano, F., Ruggeri, M., Coretti, S., Gini, E.G., Sacchini, D., Chiarico, B.E., Marchetti, M., Rodeghiero, F., Lidonnici, D.: Economic assessment of eltrombopag in the treatment of thrombocytopenia. Expert Rev. Pharmacoecon. Outcomes Res 15(4), 713–720 (2015)CrossRefGoogle Scholar
  19. 19.
    Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost- effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14(8), 1068–1077 (2011)CrossRefGoogle Scholar
  20. 20.
    Dienstag, J.L., Ghany, M.G., Morgan, T.R., HALT-C Trial Group, et al.: A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 54(2), 396–405 (2011)CrossRefGoogle Scholar
  21. 21.
    Morgan, T.R., Ghany, M.G., Kim, H.Y., et al.: HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52(3), 833–844 (2010)CrossRefGoogle Scholar
  22. 22.
    ISTAT (2014) Mortality tables. http://dati.istat.it/. Accessed Nov 2016
  23. 23.
    Sullivan, S.D., Craxi, A., Alberti, A., et al.: Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. Pharmacoeconomics 22, 257–265 (2004)CrossRefGoogle Scholar
  24. 24.
    Nakamura, J., Toyabe, S.I., Aoyagi, Y., Akazawa, K.: Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J. Viral Hepat. 15, 293–299 (2008)CrossRefGoogle Scholar
  25. 25.
    Ruggeri, M., Rolli, F.R., Romano, F., Cicchetti, A.: Valutazione economica e di Budget Impact di Zepatier nello scenario italiano. Quaderni di Ital. J. Public Health 6(6), 63–77 (2017)Google Scholar
  26. 26.
    Ministero della Salute Decreto 18 ottobre 2012. Allegato 1. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatorialeGoogle Scholar
  27. 27.
    Munari, L., Picciotto, A.: Recombinant interferon alfa-2b therapy for chronic hepatitis C in Italy: an economic analysis. FORUM Trends Exp. Clin. Med. 6, 347–353 (1996)Google Scholar
  28. 28.
    Briggs, A.H., Weinstein, M.C., Fenwick, E.A., Karnon, J., Sculpher, M.J., Paltiel, A.D., ISPOR-SMDM Modeling Good Research Practices Task Force: Model parameter estimation and uncertainty: a report of the ISPOR- SMDM modeling good research practices task force- 6. Value Health 15(6), 835–842 (2012)CrossRefGoogle Scholar
  29. 29.
    Claxton, K.: Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 26(9), 781–798 (2008)CrossRefGoogle Scholar
  30. 30.
    Gruppo multidisciplinare sui farmaci per l’epatite C cronica della Regione Emilia-Romagna. Nuovi antivirali diretti nella terapia dell’epatite C cronica. Aggiornamento settembre 2016;Google Scholar
  31. 31.
    World Health Organization: Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. World Health Organization, Geneva (2016)Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • F. R. Rolli
    • 1
  • M. Ruggeri
    • 1
  • F. Kheiraoui
    • 3
    • 4
  • C. Drago
    • 2
  • M. Basile
    • 1
  • C. Favaretti
    • 4
  • A. Cicchetti
    • 1
  1. 1.Catholic University of Sacred HeartRomeItaly
  2. 2.“Nicolò Cusano” UniversityRomeItaly
  3. 3.Istituto di Sanità Pubblica, Sezione IgieneCatholic University of Sacred HeartRomeItaly
  4. 4.VIHTALI, Value in Health Technology and Academy for Leadership and Innovation Spin-Off of the Catholic University of Sacred HeartRomeItaly

Personalised recommendations